ReST Therapeutics
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM) (NCT05921929) | ReST Therapeutics | 2024-05-02 |
Track ReST Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.